CSL Ltd (ASX: CSL) shares have passed $180 this week and are now eyeing the $200 mark. At the time of writing, the share price is $180.04, up 6% for the month and 27% over the past 6 months. Zooming out, CSL shares are still 10% lower over 12 months.
The ASX biotech stock has been through a difficult period. Earnings have faced pressure, Vifor has become a headache, and investors have questioned when the company's growth engine will fire again. Now, the focus is shifting to recovery.
Here are three things that could determine whether CSL shares will actually get there.
Image source: Getty Images
1. Behring needs to fire
The first — and arguably most important — piece of the puzzle is CSL's plasma therapies business, Behring.
Management is targeting mid-single-digit revenue growth in FY27, with immunoglobulin growth expected to land in the mid-to-high single digits. That's encouraging on its own.
But revenue growth alone won't cut it. Investors will want to see that growth flow through to the bottom line. If Behring can deliver stronger volumes while improving profitability, CSL's earnings trajectory could start looking considerably more attractive.
2. Vifor needs to become less of a problem
Then there's Vifor. Management expects Vifor revenue to decline by around 25% in FY27 amid generic competition and other headwinds. That's a sizeable drag on the group.
The good news for CSL shareholders is that the rest of the business doesn't need Vifor to boom. It needs Behring and Seqirus to demonstrate enough momentum to offset the weakness.
If that happens, investors may increasingly look beyond Vifor's near-term problems and toward CSL's longer-term earnings potential instead.
3. Margins need to expand
The third catalyst is efficiency. CSL delivered around US$176 million of cost savings in FY26 and is targeting further transformation savings in FY27.
That matters because margin expansion can turbocharge earnings growth. If CSL can grow revenue while simultaneously trimming its cost base, earnings could grow faster than sales.
And that's the kind of dynamic that gives investors a reason to reassess how much they're willing to pay for CSL shares.
So, what about $200?
CSL's FY27 guidance currently calls for roughly 5% underlying NPAT growth at constant currency. So a sustained move above $200 may ultimately require investors to believe FY27 is the starting point of a multi-year earnings recovery, rather than the end of one.
Behring growth, margin expansion, and a stabilising Vifor business could therefore be the three ingredients CSL needs to pull this off.
There's also a potential kicker sitting quietly in the background. CSL plans to buy back another A$1.1 billion of shares in FY27, which could provide additional support to earnings per share even without a single extra dollar of revenue.
